These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Main C; Pitt M; Moxham T; Stein K Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488 [TBL] [Abstract][Full Text] [Related]
67. Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. Lew TE; Cheah CY; Carney DA; Prince HM; Wolf M; Bazargan A; Januszewicz EH; Filshie R; Westerman D; Seymour JF; Tam CS Leuk Lymphoma; 2016 May; 57(5):1044-53. PubMed ID: 26464106 [TBL] [Abstract][Full Text] [Related]
68. Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Frankfurt O; Ma S; Gordon L; Winter JN; Horowitz JM; Rademaker A; Weitner BB; Peterson LC; Altman JK; Tallman MS; Petrich A; Rosen ST Leuk Lymphoma; 2015 Feb; 56(2):315-23. PubMed ID: 24707943 [TBL] [Abstract][Full Text] [Related]
69. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311 [TBL] [Abstract][Full Text] [Related]
70. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528 [TBL] [Abstract][Full Text] [Related]
71. Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization. Gerrie AS; Huang SJ; Bruyere H; Dalal C; Hrynchak M; Karsan A; Ramadan KM; Smith AC; Tyson C; Toze CL; Gillan TL Cancer Genet; 2014; 207(7-8):316-25. PubMed ID: 25441686 [TBL] [Abstract][Full Text] [Related]
72. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317 [TBL] [Abstract][Full Text] [Related]
73. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials. Vidal L; Gurion R; Ram R; Raanani P; Bairey O; Robak T; Gafter-Gvili A; Shpilberg O Leuk Lymphoma; 2016 Sep; 57(9):2047-57. PubMed ID: 26980554 [TBL] [Abstract][Full Text] [Related]
75. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. Michallet AS; Cazin B; Bouvet E; Oberic L; Schlaifer D; Mosser L; Salles G; Coiffier B; Laurent G; Ysebaert L J Geriatr Oncol; 2013 Apr; 4(2):141-7. PubMed ID: 24071539 [TBL] [Abstract][Full Text] [Related]
76. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population. Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606 [TBL] [Abstract][Full Text] [Related]
77. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497 [TBL] [Abstract][Full Text] [Related]
78. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade. Zoellner AK; Höhler T; Fries S; Böhme A; Kiewe P; Kellermann L; Dreyling M Ann Hematol; 2016 May; 95(6):853-61. PubMed ID: 27021305 [TBL] [Abstract][Full Text] [Related]
79. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022 [TBL] [Abstract][Full Text] [Related]
80. Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study). Szász R; Altai E; Pál K; Dombi P; Iványi J; Jakucs J; Jóni N; Illés Á; Tárkányi I; Szerafin L; Nagy Z; Farkas P; Nagy Á; Piukovics K; Ujj G; Schneider T Pathol Oncol Res; 2019 Apr; 25(2):535-540. PubMed ID: 30361908 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]